Prophylaxis of herpesvirus infections in immunocompetent and immunocompromised older patients

Drugs and Aging

Volumn 19, Issue 5, 2002, Pages 343-354

  Fillet, Anne Marie ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CHICKENPOX VACCINE; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; HERPES VACCINE; PENCICLOVIR; PROBENECID; VALACICLOVIR; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGED; ANTIVIRAL ACTIVITY; CYTOMEGALOVIRUS; DOSE RESPONSE; EPSTEIN BARR VIRUS; EYE INFECTION; HERPES; HERPES VIRUS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; INFECTION PREVENTION; NEUTROPENIA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STEM CELL TRANSPLANTATION; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS REACTIVATION; VIRUS TRANSMISSION;

EID: 0036073807     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219050-00003     Document Type: Review

References (70)

1. Infections in organ transplant recipients
2. Herpes simplex virus
3. Adull susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous exposure
4. Varicella-zosler virus
5. Cylomegalovirus
6. Human herpesvirus 6 and human herpesvirus 7
7. Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex
8. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population
9. Report of theouncil on scientific affairs. American Medical Association: Immunization of healthcare workers with varicella vaccine
10. Guideline for isolation precautions in hospitals. The hospital infection control practices advisory committee
11. Antiviral drugs
12. Antiviral agents
13. Famciclovir for ophthalmic zoster: A randomized aciclovir controlled study
14. Prevention of herpes simplex and varicella zoster infections in patients with HIV infections
15. Prophylaxis against herpesvirus infections in transplant recipients
16. Treatment of recurrent genital herpes simplex virus infections with oral acyclovir: A controlled trial
17. Cornée-conjonctive, atteintes herpétiques
18. Acyclovir halts progression of herpes zoster in immunocompromised patients
19. Valacyclovir versus acyclovir in patient initiated treatment of recurrent genital herpes: A randomized, double-blind clinical trial
20. Superior intraocular penetration of aciclovir after valaciclovir in comparison with oral aciclovir
21. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: Two randomized trials
22. Valacyclovir compared with acyclovir for improved therapy of herpes zoster
23. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: A multicenter, double-blind, placebo-controlled trial
24. Famciclovir for the suppression of symplomatic and asymptomatic herpes simplex virus reaclivalion in HIV-infected persons: A double-blind, placebo-controlled trial
25. Famciclovir for the treatment of acule herpes zoster: Effects on acute disease and postherpetic neuralgia
26. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus relinitis
27. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients
28. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis
29. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation
30. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS
31. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
32. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation
33. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial
34. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: The HPMPC peripheral cytomegalovirus retinitis trial
35. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts
36. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
37. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation
38. Valaciclovir: A review of its use in the management of herpes zoster
39. Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by cytomegalovirus UL97 protein: A quantitative analysis using recombinant vaccinia viruses
40. Mode of antiviral action of penciclovir in MRC-5 infected cells with herpes simplex virus type 1 (HSV-I), HSV-2 and varicella-zoster virus
41. Ganciclovir
42. Vaiganciclovir
43. Immune responses of elderly persons four years after receiving a live attenuated varicella vaccine
44. Vaccination of immunocompetent elderly subjects with a live attenuated oka strain of varicella zoster virus: A randomized, controlled, dose response trial
45. Herpes simplex virus vaccine in recurrent herpetic ocular infection
46. Zoster immune globulin. A further assessment
47. Epidemiology of ocular herpes simplex: Incidence in Rochester, Minnesota, 1950 through 1982
48. Acyclovir for the prevention of recurrent herpes simplex virus eye disease
49. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: Effect of acyclovir treatment
50. New therapies and prevention strategies for genital herpes
51. Neuroepidemiology
52. Pain and its persistence in herpes zoster
53. Postherpetic neuralgia -pathogenesis, treatment, prevention
54. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster
55. Prednisolone does not prevent postherpetic neuralgia
56. Acyclovir with and without prednisone for the treatment of herpes zoster: A randomized placebo-controlled trial
57. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella specific immune response in seropositive people 55 years of age and older
58. Oral-acyclovir to suppress recurring herpes simplex virus infection in immunodeficient patients
59. Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients
60. Evaluation of varicella-zoster immune globulin: Protection of immunosuppressed children after household exposure to varicella
61. Discontinuation of maintenance therapy for CMV retinitis in HIV-infected patients receiving highly active antiretrovirai therapy
62. Plasma CMV DNA, pp65 antigenemia and a low CD4 count remain risk factors for CMV disease in patients receiving HAART
63. Value of markers for cytomegalovirus (CMV) infection for the occurrence of CMV disease in human immunodeficiency virus (HIV) infected patients receiving highly active antiretroviral therapy: The PREDIVIR study (P117)
64. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegaiovirus in solid organ transplant recipients
65. Prevention of cytomegaiovirus disease in recipients of solid-organ transplants
66. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
67. Allograft rejection predicts the occurence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir
68. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone narrow transplantation
69. A randomized, controlled trial of prophylactic ganaiclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
70. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection